Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-09-05

Clinical Trial Update: Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML) [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial of Brentuximab in combination with 5-azacytidine for leukemia was terminated; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • 5-Azacytidine (5-azacytidine)
  • Brentuximab (brentuximab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2017-09-05